Pseudotype-based neutralization assays for influenza: A systematic analysis

Frontiers in Immunology

Volumn 6, Issue MAR, 2015, Pages

  Carnell, George William ^a   Ferrara, Francesca ^a   Grehan, Keith ^a   Thompson, Craig Peter ^a,b   Temperton, Nigel James ^a  

^a MEDWAY SCHOOL OF PHARMACY   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

Hemagglutinin; Influenza; Lentiviral vector; Neutralization assay; Pseudotype; Retroviral vector; Universal vaccine

Indexed keywords

GREEN FLUORESCENT PROTEIN; HEMAGGLUTININ; LENTIVIRUS VECTOR; NEUTRALIZING ANTIBODY; PROTEIN M2; PROTEINASE; RETROVIRUS VECTOR; VIRUS SIALIDASE;

ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CROSS REACTION; DIAGNOSTIC ACCURACY; FLUORESCENCE ACTIVATED CELL SORTER; GENE EXPRESSION; GENETIC TRANSDUCTION; GENETIC TRANSFECTION; HEMAGGLUTINATION INHIBITION; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNOGENICITY; INFLUENZA; MURINE LEUKEMIA VIRUS; NONHUMAN; REPRODUCIBILITY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY ANALYSIS; SERODIAGNOSIS; SYSTEMATIC REVIEW; VACCINATION; VESICULOVIRUS; VIRUS INFECTION; WESTERN BLOTTING;

EID: 84926670872     PISSN: None     EISSN: 16643224     Source Type: Journal    
DOI: 10.3389/fimmu.2015.00161     Document Type: Article

References (171)

1. Ahmed, M. S., Jacques, L. C., Mahallawi, W., Ferrara, F., Temperton, N., Upile, N., Vaughan, C., Sharma, R., Beer, H., Hoschler, K., et al. (2015). Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection. Antiviral Res. 114, 106-112. doi:10.1016/j.antiviral.2014.12.008.
2. Alberini, I., Del Tordello, E., Fasolo, A., Temperton, N. J., Galli, G., Gentile, C., Montomoli, E., Hilbert, A. K., Banzhoff, A., Del Giudice, G., et al. (2009). Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 influenza viruses. Vaccine 27, 5998-6003. doi:10.1016/j.vaccine.2009.07.079.
3. Alvarado-Facundo, E., Gao, Y., Ribas-Aparicio, R. M., Jiménez-Alberto, A., Weiss, C. D., and Wang, W. (2015). Influenza Virus M2 Protein Ion Channel Activity Helps To Maintain Pandemic 2009 H1N1 Virus Hemagglutinin Fusion Competence during Transport to the Cell Surface. J. Virol. 89, 1975-1985. doi:10.1128/JVI.03253-14.
4. Ao, Z., Patel, A., Tran, K., He, X., Fowke, K., Coombs, K., Kobasa, D., Kobinger, G., and Yao, X. (2008). Characterization of a trypsin-dependent avian influenza H5N1-pseudotyped HIV vector system for high throughput screening of inhibitory molecules. Antiviral Res. 79, 12-18. doi:10.1016/j.antiviral.2008.02.001.
5. Arnold, A. S., Laporte, V., Dumont, S., Appert-Collin, A., Erbacher, P., Coupin, G., Levy, R., Poindron, P., and Gies, J. P. (2006). Comparing reagents for efficient transfection of human primary myoblasts: FuGENE 6, Effectene and ExGen 500. Fundam. Clin. Pharmacol. 20, 81-89. doi:10.1111/j.1472-8206.2005.00344.x.
6. Ascione, A., Capecchi, B., Campitelli, L., Imperiale, V., Flego, M., Zamboni, S., Gellini, M., Alberini, I., Pittiglio, E., Donatelli, I., et al. (2009). Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1. Antiviral Res. 83, 238-44. doi:10.1016/j.antiviral.2009.05.005.
7. Banasik, M. B., and McCray, P. B. (2010). Integrase-defective lentiviral vectors: progress and applications. Gene Ther. 17, 150-157. doi:10.1038/gt.2009.135.
8. Basu, A., Antanasijevic, A., Wang, M., Li, B., Mills, D. M., Ames, J. a, Nash, P. J., Williams, J. D., Peet, N. P., Moir, D. T., et al. (2013). New Small Molecule Entry Inhibitors Targeting Hemagglutinin-mediated Influenza A Virus Fusion. J. Virol. 88, 1447-60. doi:10.1128/JVI.01225-13.
9. Benfield, C., Smith, S. E., Wright, E., Wash, R. S., Ferrara, F., Temperton, N. J., and Kellam, P. (2015). Bat and pig Interferon-Induced Transmembrane Protein 3 restrict cell entry by influenza virus and lyssaviruses. J. Gen. Virol. doi:10.1099/vir.0.000058.
10. Bertram, S., Glowacka, I., Blazejewska, P., Soilleux, E., Allen, P., Danisch, S., Steffen, I., Choi, S.-Y., Park, Y., Schneider, H., et al. (2010). TMPRSS2 and TMPRSS4 facilitate trypsin-independent spread of influenza virus in Caco-2 cells. J. Virol. 84, 10016-10025. doi:10.1128/JVI.00239-10.
11. Bertram, S., Heurich, A., Lavender, H., Gierer, S., Danisch, S., Perin, P., Lucas, J. M., Nelson, P. S., Pöhlmann, S., and Soilleux, E. J. (2012). Influenza and SARS-coronavirus activating proteases TMPRSS2 and HAT are expressed at multiple sites in human respiratory 807 and gastrointestinal tracts. PLoS One 7, 1-8. doi:10.1371/journal.pone.0035876.
12. Blesch, A. (2004). Lentiviral and MLV based retroviral vectors for ex vivo and in vivo gene transfer. Methods 33, 164-172. doi:10.1016/j.ymeth.2003.11.005.
13. Bock, M., Bishop, K. N., Towers, G., and Stoye, J. P. (2000). Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol. 74, 7422-7430. doi:10.1128/JVI.74.16.7422-7430.2000.
14. Bosch, V., Kramer, B., Pfeiffer, T., Stärck, L., and Steinhauer, D. a. (2001). Inhibition of release of lentivirus particles with incorporated human influenza virus haemagglutinin by binding to sialic acid-containing cellular receptors. J. Gen. Virol. 82, 2485-2494.
15. Böttcher, E., Matrosovich, T., Beyerle, M., Klenk, H.-D., Garten, W., and Matrosovich, M. (2006). Proteolytic activation of influenza viruses by serine proteases TMPRSS2 and HAT from human airway epithelium. J. Virol. 80, 9896-9898. doi:10.1128/JVI.01118-06.
16. Boussif, O., Lezoualc'h, F., Zanta, M. a, Mergny, M. D., Scherman, D., Demeneix, B., and Behr, J. P. (1995). A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc. Natl. Acad. Sci. U. S. A. 92, 7297-7301. doi:10.1073/pnas.92.16.7297.
17. Buchy, P., Vong, S., Chu, S., Garcia, J.-M., Hien, T. T., Hien, V. M., Channa, M., Ha, D. Q., Chau, N. V. V., Simmons, C., et al. (2010). Kinetics of neutralizing antibodies in patients naturally infected by H5N1 virus. PLoS One 5, e10864. doi:10.1371/journal.pone.0010864.
18. Chaipan, C., Kobasa, D., Bertram, S., Glowacka, I., Steffen, I., Tsegaye, T. S., Takeda, M., Bugge, T. H., Kim, S., Park, Y., et al. (2009a). Proteolytic activation of the 1918 influenza virus hemagglutinin. J. Virol. 83, 3200-3211. doi:10.1128/JVI.02205-08.
19. Chen, M.-W., Cheng, T.-J. R., Huang, Y., Jan, J.-T., Ma, S.-H., Yu, A. L., Wong, C.-H., and Ho, D. D. (2008). A consensus-hemagglutinin-based DNA vaccine that protects mice against divergent H5N1 influenza viruses. Proc. Natl. Acad. Sci. U. S. A. 105, 13538-13543. doi:10.1073/pnas.0806901105.
20. Chen, M.-W., Liao, H.-Y., Huang, Y., Jan, J.-T., Huang, C.-C., Ren, C.-T., Wu, C.-Y., Cheng, T.-J. R., Ho, D. D., and Wong, C.-H. (2011). Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc. Natl. Acad. Sci. U. S. A. 108, 3510-3515. doi:10.1073/pnas.1019744108.
21. Cheresiz, S. V., Kononova, A. A., Razumova, Y. V., Dubich, T. S., Chepurnov, A. A., Kushch, A. A., Davey, R., and Pokrovsky, a. G. (2014). A vesicular stomatitis pseudovirus expressing the surface glycoproteins of influenza A virus. Arch. Virol. 159, 2651-2658. doi:10.1007/s00705-014-2127-y.
22. Corti, D., Suguitan, A. L., Pinna, D., Silacci, C., Fernandez-Rodriguez BM, Vanzetta, F., Santos, C., Luke, C. J., Torres-Velez FJ, Temperton, N. J., et al. (2010). Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine. J. Clin. Invest. 120, 1663-1673. doi:10.1172/jci41902.
23. Corti, D., Voss, J., Gamblin, S. J., Codoni, G., Macagno, A., Jarrossay, D., Vachieri, S. G., Pinna, D., Minola, A., Vanzetta, F., et al. (2011). A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850-856. doi:10.1126/science.1205669.
24. Coughlan, L., Mullarkey, C., and Gilbert, S. (2015). Adenoviral vectors as novel vaccines for influenza. J. Pharm. Pharmacol. doi:10.1111/jphp.12350.
25. Ding, H., Tsai, C., Zhou, F., Buchy, P., Deubel, V., and Zhou, P. (2011). Heterosubtypic antibody response elicited with seasonal influenza vaccine correlates partial protection against highly pathogenic H5N1 virus. PLoS One 6, e17821. doi:10.1371/journal.pone.0017821.
26. Du, L., Zhao, G., Zhang, X., Liu, Z., Yu, H., Zheng, B. J., Zhou, Y., and Jiang, S. (2010). Development of a safe and convenient neutralization assay for rapid screening of influenza HA-specific neutralizing monoclonal antibodies. Biochem. Biophys. Res. Commun. 397, 580-585. doi:10.1016/j.bbrc.2010.05.161.
27. Du, N., Zhou, J., Lin, X., Zhang, Y., Yang, X., Wang, Y., and Shu, Y. (2010). Differential activation of {NK} cells by influenza A pseudotype {H5N1} and 1918 and 2009 pandemic {H1N1} viruses. J. Virol. 84, 7822-7831. doi:10.1128/JVI.00069-10.
28. Edgar, R. C. (2004). MUSCLE: a multiple sequence alignment method with reduced time and space complexity. BMC Bioinformatics 5, 113. doi:10.1186/1471-2105-5-113.
29. Edwards, M. J., and Dimmock, N. J. (2001). Hemagglutinin 1-specific immunoglobulin G and Fab molecules mediate postattachment neutralization of influenza A virus by inhibition of an early fusion event. J. Virol. 75, 10208-10218. doi:10.1128/JVI.75.21.10208-10218.2001.
30. Ekiert, D. C., Bhabha, G., Elsliger, M., Friesen, R. H. E., Throsby, M., Goudsmit, J., and Wilson, I. a (2010). Antibody recognition of a highly conserved influenza virus epitope: implications for universal prevention and therapy. 324, 246-251. doi:10.1126/science.1171491.Antibody.
31. Ekiert, D. C., Friesen, R. H. E., Bhabha, G., Kwaks, T., Yu, W., Ophorst, C., Cox, F., Korse, H. J. W. M., Vogels, R., Brakenhoff, J. P. J., et al. (2012). A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses. 333, 843-850. doi:10.1126/science.1204839.A.
32. Engelman, A., and Cherepanov, P. (2012). The structural biology of HIV-1: mechanistic and therapeutic insights. Nat. Rev. Microbiol. 10, 279-290. doi:10.1038/nrmicro2747.
33. WHO Fact sheet N°211 (2014). Available at: http://www.who.int/mediacentre/factsheets/fs211/en/
34. Farazmandfar, T., Shahreza, H. K., Haghshenas, M. R., Janbabai, G., Azadeh, H., and Samaei, N. M. (2012). Use of integrase-minus lentiviral vector for transient expression. Cell J. 14, 76-81.
35. Farrell, K. B., Ting, Y.-T., and Eiden, M. V (2002). Fusion-defective gibbon ape leukemia virus vectors can be rescued by homologous but not heterologous soluble envelope proteins. J. Virol. 76, 4267-4274. doi:10.1128/JVI.76.9.4267-4274.2002.
36. Felgner, P. L., Gadek, T. R., Holm, M., Roman, R., Chan, H. W., Wenz, M., Northrop, J. P., Ringold, G. M., and Danielsen, M. (1987). Lipofection: a highly efficient, lipid892 mediated DNA-transfection procedure. Proc. Natl. Acad. Sci. U. S. A. 84, 7413-7417. doi:10.1073/pnas.84.21.7413.
37. Ferrara, F., Molesti, E., Böttcher-Friebertshäuser, E., Cattoli, G., Corti, D., Scott, S. D., and Temperton, N. J. (2012). The human Transmembrane Protease Serine 2 is necessary for the production of Group 2 influenza A virus pseudotypes. J. Mol. Genet. Med. 7, 309-14.
38. Ferrara, F., Molesti, E., and Temperton, N. (2015). The application of pseudotypes to Influenza pandemic preparedness. Future Virol., In press.
39. Finer, B. M. H., Dull, T. J., Qin, L., Farson, D., and Roberts, M. R. (1994). kat: A High-Efficiency Retroviral Transduction System for Primary Human T Lymphocytes. 83, 43-50.
40. Fleury, D., Wharton, S. A., Skehel, J. J., Knossow, M., and Bizebard, T. (1998). Antigen distortion allows influenza virus to escape neutralization. Nat. Struct. Biol. 5, 119-23. Available at: http://www.ncbi.nlm.nih.gov/pubmed/9461077 [Accessed February 28, 2015].
41. Fouchier, R. A. M., Munster, V., Wallensten, A., Bestebroer, T. M., Herfst, S., Smith, D., Rimmelzwaan, G. F., Olsen, B., and Osterhaus, A. D. M. E. (2005). Characterization of a novel influenza A virus hemagglutinin subtype (H16) obtained from black-headed gulls. J. Virol. 79, 2814-22. doi:10.1128/JVI.79.5.2814-2822.2005.
42. Galloway, S. E., Reed, M. L., Russell, C. J., and Steinhauer, D. A. (2013). Influenza HA subtypes demonstrate divergent phenotypes for cleavage activation and pH of fusion: implications for host range and adaptation. {PLoS} Pathog. 9. doi:10.1371/journal.ppat.1003151.
43. Garcia, J., and Lai, J. C. (2011). Production of Influenza pseudotyped lentiviral particles and their use in influenza research and diagnosis: an update. 9.
44. Garcia, J. M., Lagarde, N., Ma, E. S. K., de Jong, M. D., and Peiris, J. S. M. (2010). Optimization and evaluation of an influenza A (H5) pseudotyped lentiviral particle919 based serological assay. J. Clin. Virol. 47, 29-33. doi:10.1016/j.jcv.2009.10.009.
45. Garcia, J. M., Pepin, S., Lagarde, N., Ma, E. S. K., Vogel, F. R., Chan, K. H., Chiu, S. S. S., and Peiris, J. S. M. (2009). Heterosubtype neutralizing responses to influenza A (H5N1) viruses are mediated b 922 y antibodies to virus haemagglutinin. PLoS One 4, 1-6. doi:10.1371/journal.pone.0007918.
46. Garten, W., and Klenk, H. (2008). Avian Influenza. eds. H.-D. Klenk, M. N. Matrosovich, and J. Stech Basel: KARGER doi:10.1159/000151618.
47. Giddings, A. M., and Olsen, J. C. (2013). High efficiency gene transfer to airways of mice using Influenza hemagglutinin pseudotyped lentiviral vectors. 51-62. doi:10.1002/jgm.
48. Gorres, J. P., Lager, K. M., Kong, W. P., Royals, M., Todd, J. P., Vincent, A. L., Wei, C. J., Loving, C. L., Zanella, E. L., Janke, B., et al. (2011). DNA vaccination elicits protective immune responses against pandemic and classic swine influenza viruses in pigs. Clin. Vaccine Immunol. 18, 1987-1995. doi:10.1128/CVI.05171-11.
49. Graham, F, L., and Van Der Eb, A, J. (1973). A new technique for the assay of infectivity of human adenovirus 5 DNA. Virology 52, 456-467.
50. Hai, R., Krammer, F., Tan, G. S., Pica, N., Eggink, D., Maamary, J., Margine, I., Albrecht, R. A., and Palese, P. (2012). Influenza Viruses Expressing Chimeric Hemagglutinins: Globular Head and Stalk Domains Derived from Different Subtypes. J. Virol. 86, 5774-5781. doi:10.1128/JVI.00137-12.
51. Hanika, A., Larisch, B., Steinmann, E., Christel, S.-W., Herrler, G., and Zimmer, G. (2005). Use of influenza C virus glycoprotein {HEF} for generation of vesicular stomatitis virus pseudotypes. J. Gen. Virol. 86, 1455-1465. doi:10.1099/vir.0.80788-0.
52. Hartley, J. W., Rowe, W. P., and Huebner, R. J. (1970). Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. J. Virol. 5, 221-225.
53. Hashem, A. M., Van Domselaar, G., Li, C., Wang, J., She, Y. M., Cyr, T. D., Sui, J., He, R., Marasco, W. A., and Li Xuguang, X. (2010). Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus. Biochem. Biophys. Res. Commun. 403, 247-251. doi:10.1016/j.bbrc.2010.11.030.
54. Hatziioannou, T., Delahaye, E., Martin, F., Russell, S. J., and Cosset, F. L. (1999). Retroviral display of functional binding domains fused to the amino terminus of influenza hemagglutinin. Hum. Gene Ther. 10, 1533-1544. doi:10.1089/10430349950017860.
55. Hatziioannou, T., Valsesia-Wittmann, S., Russell, S. J., and Cosset, F. L. (1998). Incorporation of fowl plague virus hemagglutinin into murine leukemia virus particles and analysis of the infectivity of the pseudotyped retroviruses. J. Virol. 72, 5313-5317.
56. Hause, B. M., Collin, E. A., Liu, R., Huang, B., Sheng, Z., Lu, W., Wang, D., Nelson, E. A., and Li, F. (2014). Characterization of a novel influenza virus in cattle and swine: Proposal for a new genus in the Orthomyxoviridae family. MBio 5, 1-10. doi:10.1128/mBio.00031-14.
57. Haynes, J. R., Dokken, L., Wiley, J. A., Cawthon, A. G., Bigger, J., Harmsen, A. G., and Richardson, C. (2009). Influenza-pseudotyped Gag virus-like particle vaccines provide broad protection against highly pathogenic avian influenza 959 challenge. Vaccine 27, 530-541. doi:10.1016/j.vaccine.2008.11.011.
58. Hofmann, C., Sandig, V., Jennings, G., Rudolph, M., Schlag, P., and Strauss, M. (1995). Efficient gene transfer into human hepatocytes by baculovirus vectors. Proc. Natl. Acad. Sci. U. S. A. 92, 10099-103.
59. Hooper, K. A, and Bloom, J. D. (2013). A mutant influenza virus that uses an N1 neuraminidase as the receptor-binding protein. J. Virol. 87, 12531-40. doi:10.1128/JVI.01889-13.
60. Hooper, K. A., Crowe, J. E., and Bloom, J. D. (2015). Influenza viruses with receptor-binding N1 neuraminidases occur sporadically in several lineages and show no attenuation in cell culture or mice. J. Virol., JVI.00012-15. doi:10.1128/JVI.00012-15.
61. Hu, H., Voss, J., Zhang, G., Buchy, P., Zuo, T., Wang, L., Wang, F., Zhou, F., Wang, G., Tsai, C., et al. (2012). A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza {H5N1} viruses. J. Virol. 86, 2978-2989. doi:10.1128/jvi.06665-11.
62. Huang, I. C., Bailey, C. C., Weyer, J. L., Radoshitzky, S. R., Becker, M. M., Chiang, J. J., Brass, A. L., Ahmed, A. A., Chi, X., Dong, L., et al. (2011). Distinct patterns of IFITM976 mediated restriction of filoviruses, SARS coronavirus, and influenza A virus. PLoS Pathog. 7. doi:10.1371/journal.ppat.1001258.
63. Huang, I.-C., Li, W., Sui, J., Marasco, W., Choe, H., and Farzan, M. (2008). Influenza A virus neuraminidase limits viral superinfection. J. Virol. 82, 4834-43. doi:10.1128/JVI.00079-08.
64. Hultberg, A., Temperton, N. J., Rosseels, V., Koenders, M., Gonzalez-Pajuelo, M., Schepens, B., Ibañez, L. I., Vanlandschoot, P., Schillemans, J., Saunders, M., et al. (2011). Llama983 derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules. PLoS One 6, e17665. doi:10.1371/journal.pone.0017665.
65. Jacks, T., Power, M. D., Masiarz, F. R., Luciw, P. A., Barr, P. J., and Varmus, H. E. (1988). Characterization of ribosomal frameshifting in HIV-1 gag-pol expression. Nature 331, 280-3. doi:10.1038/331280a0.
66. Kanekiyo, M., Wei, C.-J., Yassine, H. M., McTamney, P. M., Boyington, J. C., Whittle, J. R. R., Rao, S. S., Kong, W.-P., Wang, L., and Nabel, G. J. (2013). Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies. Nature 499, 102-6. doi:10.1038/nature12202.
67. Kong, W.-P., Hood, C., Yang, Z.-Y., Wei, C.-J., Xu, L., García-Sastre, A., Tumpey, T. M., and Nabel, G. J. (2006). Protective immunity to lethal challenge of the 1918 pandemic influenza virus by vaccination. Proc. Natl. Acad. Sci. U. S. A. 103, 15987-15991.
68. Kostka, V., and Carpenter, F. H. (1964). Inhibition of Chymotrypsin Activity in Crystalline Trypsin Preparations. J. Biol. Chem. 239, 1799-1803.
69. Krammer, F., Hai, R., Yondola, M., Tan, G. S., Leyva-Grado, V. H., Ryder, A. B., Miller, M. S., Rose, J. K., Palese, P., García-Sastre, A., et al. (2014). Assessment of influenza virus hemagglutinin stalk-based immunity in ferrets. J. Virol. 88, 3432-42. doi:10.1128/JVI.03004-13.
70. Krammer, F., Margine, I., Hai, R., Flood, A., Hirsh, A., Tsvetnitsky, V., Chen, D., and Palese, P. (2013a). H3 Stalk-Based Chimeric Hemagglutinin Influenza Virus Constructs Protect Mice from H7N9 Challenge. J. Virol. 88, 2340-2343. doi:10.1128/JVI.03183-13.
71. Krammer, F., Pica, N., Hai, R., Margine, I., and Palese, P. (2013b). Chimeric Hemagglutinin Influenza Virus Vaccine Constructs Elicit Broadly Protective Stalk-Specific Antibodies. J. Virol. 87, 6542-6550. doi:10.1128/JVI.00641-13.
72. Krammer, F., Pica, N., Hai, R., Tan, G. S., and Palese, P. (2012). Hemagglutinin Stalk-Reactive Antibodies Are Boosted following Sequential Infection with Seasonal and Pandemic H1N1 Influenza Virus in Mice. J. Virol. 86, 10302-10307. doi:10.1128/JVI.01336-12.
73. Labrosse, B., Tourdjman, M., Porcher, R. L., Legoff, J., de Lamballerie, X., Simon, F., Molina, J. M., and Clavel, F. (2010). Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 influenza viruses using a pseudotype neutralization assay. PLoS One 5, 4-7. doi:10.1371/journal.pone.0011036.
74. Ledgerwood, J. E., Hu, Z., Gordon, I. J., Yamshchikov, G., Enama, M. E., Plummer, S., Bailer, R., Pearce, M. B., Tumpey, T. M., Koup, R. A., et al. (2012). Influenza virus h5 {DNA} vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin. vaccine Immunol. {CVI} 19, 1792-1797. doi:10.1128/CVI.05663-11.
75. Ledgerwood, J. E., Wei, C. J., Hu, Z., Gordon, I. J., Enama, M. E., Hendel, C. S., McTamney, P. M., Pearce, M. B., Yassine, H. M., Boyington, J. C., et al. (2011). DNA priming and influenza vaccine immunogenicity: Two phase 1 open label randomised clinical trials. Lancet Infect. Dis. 11, 916-924. doi:10.1016/S1473-3099(11)70240-7.
76. Ledgerwood, J. E., Zephir, K., Hu, Z., Wei, C. J., Chang, L., Enama, M. E., Hendel, C. S., Sitar, S., Bailer, R. T., Koup, R. A., et al. (2013). Prime-boost interval matters: A randomized phase 1 study to identify the minimum interval necessary to observe the h5 dna influenza vaccine priming effect. J. Infect. Dis. 208, 418-422. doi:10.1093/infdis/jit180.
77. Lee, C., Senne, D. A, and Suarez, D. L. (2006). Development and Application of Reference Antisera against 15 Hemagglutinin Subtypes of Influenza Virus by DNA Vaccination of Chickens Development and Application of Reference Antisera against 15 Hemagglutinin Subtypes of Influenza Virus by DNA Vaccination. 13, 395-402. doi:10.1128/CVI.13.3.395.
78. Li, Z., Liu, Z., Ma, C., Zhang, L., Su, Y., Gao, G. F., Li, Z., Cui, L., and He, W. (2011a). Identification of amino acids in highly pathogenic avian influenza H5N1 virus hemagglutinin that determine avian influenza species specificity. Arch. Virol. 156, 1803-1812. doi:10.1007/s00705-011-1056-2.
79. Li, Z., Ma, C., Liu, Z., and He, W. (2011b). Ser 1038 ologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtype H5N1 viruses in China. Immunol. Lett. 135, 59-63. doi:10.1016/j.imlet.2010.09.012.
80. Lin, A. H., and Cannon, P. M. (2002). Use of pseudotyped retroviral vectors to analyze the receptor-binding pocket of hemagglutinin from a pathogenic avian influenza A virus (H7 subtype). Virus Res. 83, 43-56. doi:10.1016/S0168-1702(01)00407-5.
81. Lin, X., Zhou, J., Zhang, Y., Wu, J., Zhang, F., Li, Z., Zhang, Y., Bi, S., Shu, Y., and Wang, Y. (2009). Oseltamivir boosts 2009 H1N1 virus infectivity in vitro. Biochem. Biophys. Res. Commun. 390, 1305-1308. doi:10.1016/j.bbrc.2009.10.142.
82. Lingwood, D., McTamney, P. M., Yassine, H. M., Whittle, J. R. R., Guo, X., Boyington, J. C., Wei, C.-J., and Nabel, G. J. (2012). Structural and genetic basis for development of broadly neutralizing influenza antibodies. Nature 489, 566-570. doi:10.1038/nature11371.
83. Loureiro, S., Ren, J., Phapugrangkul, P., Colaco, C. a, Bailey, C. R., Shelton, H., Molesti, E., Temperton, N. J., Barclay, W. S., and Jones, I. M. (2011). Adjuvant-free immunization with hemagglutinin-Fc fusion proteins as an approach to influenza vaccines. J. Virol. 85, 3010-3014. doi:10.1128/JVI.01241-10.
84. Loyter, A, Scangos, G. A, and Ruddle, F. H. (1982). Mechanisms of DNA uptake by mammalian cells: fate of exogenously added DNA monitored by the use of fluorescent dyes. Proc. Natl. Acad. Sci. U. S. A. 79, 422-426. doi:10.1073/pnas.79.2.422.
85. Mahallawi, W. H., Kasbekar, A. V, McCormick, M. S., Hoschler, K., Temperton, N., Leong, S. C., Beer, H., Ferrara, F., McNamara, P. S., and Zhang, Q. (2013). Infection with 2009 H1N1 influenza virus primes for immunological memory in human nose-associated lymphoid tissue, offering cross-reactive immunity to H1N1 and avian H5N1 viruses. J. Virol. 87, 5331-9. doi:10.1128/JVI.03547-12.
86. Mallajosyula, V. V. A., Citron, M., Ferrara, F., Lu, X., Callahan, C., Heidecker, G. J., Sarma, S. P., Flynn, J. A., Temperton, N. J., Liang, X., et al. (2014). Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc. Natl. Acad. Sci. 111, 1-10. doi:10.1073/pnas.1402766111.
87. Margine, I., Krammer, F., Hai, R., Heaton, N. S., Tan, G. S., Andrews, S. a, Runstadler, J. a, Wilson, P. C., Albrecht, R. A, García-Sastre, A, et al. (2013). Hemagglutinin stalk-based universal vaccine constructs protect against group 2 influenza A viruses. J. Virol. 87, 10435-46. doi:10.1128/JVI.01715-13.
88. Mather, S. T., Wright, E., Scott, S. D., and Temperton, N. J. (2014). Lyophilisation of influenza, rabies and Marburg lentiviral pseudotype viruses for the development and distribution of a neutralisation-assay-based diagnostic kit. J. Virol. Methods 210, 51-58. doi:10.1016/j.jviromet.2014.09.021.
89. McKay, T., Patel, M., Pickles, R. J., Johnson, L. G., and Olsen, J. C. (2006). Influenza M2 envelope protein augments avian influenza hemagglutinin pseudotyping of lentiviral vectors. Gene Ther. 13, 715-724. doi:10.1038/sj.gt.3302715.
90. Molesti, E., Cattoli, G., Ferrara, F., Böttcher-Friebertshäuser, E., Terregino, C., and Temperton, N. (2012). The production and development of H7 Influenza virus pseudotypes for the study of humoral responses against avian viruses. J. Mol. Genet. Med. 7, 315-20.
91. Molesti, E., Ferrara, F., Lapini, G., Montomoli, E., and Temperton, N. (2014a). Discordant correlation between serological assays observed when measuring heterosubtypic responses against avian influenza H5 and H7 viruses in unexposed individuals. Biomed Res. Int. 2014. doi:10.1155/2014/231365.
92. Molesti, E., Milani, A., Terregino, C., Cattoli, G., and Temperton, N. J. (2013). Comparative serological assays for the study of h5 and h7 avian influenza viruses. Influenza Res. Treat. 2013, 286158. doi:10.1155/2013/286158.
93. Molesti, E., Wright, E., Terregino, C., Rahman, R., Cattoli, G., and Temperton, N. J. (2014b). Multiplex evaluation of influenza neutralizing antibodies with potential applicability to in-field serological studies. J. Immunol. Res. 2014. doi:10.1155/2014/457932.
94. Mullarkey, C. E., Boyd, A., Van Laarhoven, A., Lefevre, E. A., Veronica Carr, B., Baratelli, M., Molesti, E., Temperton, N. J., Butter, C., Charleston, B., et al. (2013). Improved adjuvanting of seasonal influenza vaccines: Preclinical studies of MVA-NP+M1 coadministration with inactivated influenza vaccine. Eur. J. Immunol. 43, 1940-1952. doi:10.1002/eji.201242922.
95. Naldini, L., Blömer, U., Gage, F. H., Trono, D., and Verma, I. M. (1996). Efficient transfer, integration, and sustained long-term expression of the transgene in adult rat brains injected with a lentiviral vector. Proc. Natl. Acad. Sci. U. S. A. 93, 11382-8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=38066&tool=pmcentrez&rendertype=abstract [Accessed January 16, 2015].
96. Nefkens, I., Garcia, J. M., Ling, C. S., Lagarde, N., Nicholls, J., Tang, D. J., Peiris, M., Buchy, P., and Altmeyer, R. (2007). Hemagglutinin pseudotyped lentiviral particles: Characterization of a new method for avian H5N1 influenza sero-diagnosis. J. Clin. Virol. 39, 27-33. doi:10.1016/j.jcv.2007.02.005.
97. O'Donnell, C. D., Wright, A., Vogel, L. N., Wei, C.-J., Nabel, G. J., and Subbarao, K. (2012). Effect of Priming with H1N1 Influenza Viruses of Variable Antigenic Distances on Challenge with 2009 Pandemic H1N1 Virus. J. Virol. 86, 8625-8633. doi:10.1128/JVI.00147-12.
98. Oh, H.-L. J., Akerström, S., Shen, S., Bereczky, S., Karlberg, H., Klingström, J., Lal, S. K., Mirazimi, A., and Tan, Y.-J. (2010). An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses. J. Virol. 84, 8275-8286. doi:10.1128/JVI.02593-09.
99. Oh, S., Selleck, P., Temperton, N. J., Chan, P. K. S., Capecchi, B., Manavis, J., Higgins, G., Burrell, C. J., and Kok, T. (2009). Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 viruses. J. Virol. Methods 157, 161-167. doi:10.1016/j.jviromet.2008.12.016.
100. Okuno, Y., Matsumoto, K., Isegawa, Y., and Ueda, S. (1994). Protection against the mouse1121 adapted A/FM/1/47 strain of influenza A virus in mice by a monoclonal antibody with cross-neutralizing activity among H1 and H2 strains. J. Virol. 68, 517-520.
101. Ostrowski, L. E., Yin, W., Patel, M., Sechelski, J., Rogers, T., Burns, K., Grubb, B. R., and Olsen, J. C. (2014). Restoring ciliary function to differentiated primary ciliary dyskinesia cells with a lentiviral vector. Gene Ther. 21, 253-61. doi:10.1038/gt.2013.79.
102. Pappas, L., Foglierini, M., Piccoli, L., Kallewaard, N. L., Turrini, F., Silacci, C., Fernandezrodriguez, B., Agatic, G., Giacchetto-sasselli, I., Pellicciotta, G., et al. (2014). Antibodies Through Redundant Mutations. Nature. doi:10.1038/nature13764.
103. Patel, M., Giddings, A. M., Sechelski, J., and Olsen, J. C. (2013). High efficiency gene transfer to airways of mice using influenza hemagglutinin pseudotyped lentiviral vectors. J. Gene Med. 15, 51-62. doi:10.1002/jgm.2695.
104. Pear, W. S., Nolan, G. P., Scott, M. L., and Baltimore, D. (1993). Production of high-titer helper-free retroviruses by transient transfection. 90, 8392-8396.
105. Pica, N., Hai, R., Krammer, F., Wang, T. T., Maamary, J., Eggink, D., Tan, G. S., Krause, J. C., Moran, T., Stein, C. R., et al. (2012). Hemagglutinin stalk antibodies elicited by the 2009 pandemic influenza virus as a mechanism for the extinction of seasonal H1N1 viruses. Proc. Natl. Acad. Sci. 109, 2573-2578. doi:10.1073/pnas.1200039109.
106. Powell, T. J., Silk, J. D., Sharps, J., Fodor, E., and Townsend, a. R. M. (2012). Pseudotyped Influenza A Virus as a Vaccine for the induction of Heterotypic Immunity. J. Virol. 86, 13397-406. doi:10.1128/JVI.01820-12.
107. Prodromou, C., and Pearl, L. H. (1992). Recursive PCR: a novel technique for total gene synthesis. "Protein Eng. Des. Sel. 5, 827-829. doi:10.1093/protein/5.8.827.
108. Qiu, C., Huang, Y., Wang, Q., Tian, D., Zhang, W., Hu, Y., Yuan, Z., Zhang, X., and Xu, J. (2012). Boosting heterosubtypic neutralization antibodies in recipients of 2009 pandemic H1N1 influenza vaccine. Clin. Infect. Dis. 54, 17-24. doi:10.1093/cid/cir753.
109. Qiu, C., Huang, Y., Zhang, A., Tian, D., Wan, Y., Zhang, X., Zhang, W., Zhang, Z., Yuan, Z., Hu, Y., et al. (2013). Safe Pseudovirus-based Assay for Neutralization Antibodies against Influenza A(H7N9) Virus. Emerg. Infect. Dis. 19, 1685-1687.
110. Rao, S., Kong, W. P., Wei, C. J., Yang, Z. Y., Nason, M., Styles, D., DeTolla, L. J., Sorrell, E. M., Song, H., Wan, H., et al. (2008). Multivalent HA DNA vaccination protects against highly pathogenic H5N1 avian influenza infection in chickens and mice. PLoS One 3. doi:10.1371/journal.pone.0002432.
111. Rao, S. S., Kong, W. P., Wei, C. J., Van Hoeven, N., Patrick Gorres, J., Nason, M., Andersen, H., Tumpey, T. M., and Nabel, G. J. (2010). Comparative efficacy of hemagglutinin, nucleoprotein, and matrix 2 protein gene-based vaccination against h5n1 influenza in mouse and ferret. PLoS One 5, e9812. doi:10.1371/journal.pone.0009812.g001.
112. Rossman, J. S., Jing, X., Leser, G. P., and Lamb, R. A. (2011). Influenza Virus M2 Protein Mediates ESCRT-Independent Membrane Scission. Cell 142, 902-913. doi:10.1016/j.cell.2010.08.029.Influenza.
113. Sakuma, T., Barry, M. A., and Ikeda, Y. (2012). Lentiviral vectors: basic to translational. Biochem. J. 443, 603-618. doi:10.1042/BJ20120146.
114. Sandrin, V., and Cosset, F. L. (2006). Intracellular versus cell surface assembly of retroviral pseudotypes is determined by the cellular localization of the viral glycoprotein, its capacity to interact with Gag, and the expression of the Nef protein. J. Biol. Chem. 281, 528-542. doi:10.1074/jbc. M506070200.
115. Sawoo, O., Dublineau, A., Batéjat, C., Zhou, P., Manuguerra, J.-C., and Leclercq, I. (2014). Cleavage of Hemagglutinin-Bearing Lentiviral Pseudotypes and Their Use in the Study of Influenza Virus Persistence. PLoS One 9, e106192. doi:10.1371/journal.pone.0106192.
116. Schmeisser, F., Friedman, R., Besho, J., Lugovtsev, V., Soto, J., Wang, W., Weiss, C., Williams, O., Xie, H., Ye, Z., et al. (2013). Neutralizing and protective epitopes of the 2009 pandemic influenza {H1N1} hemagglutinin. Influenza Other Respi. Viruses 7, 480-490. doi:10.1111/irv.12029.
117. Scott, S., Molesti, E., Temperton, N., Ferrara, F., Böttcher-Friebertshäuser, E., and Daly, J. (2012). The use of equine influenza pseudotypes for serological screening. J. Mol. Genet. Med. 6, 304-8. Available at: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3601075&tool=pmcentrez&rendertype=abstract.
118. Shahsavandi, S., Salmanian, A.-H., Ghorashi, S. A., Masoudi, S., Fotouhi, F., and Ebrahimi, M. M. (2011). Specific subtyping of influenza A virus using a recombinant hemagglutinin protein expressed in baculovirus. Mol. Biol. Rep. 38, 3293-8. doi:10.1007/s11033-010-0434-2.
119. Shelton, H., Roberts, K. L., Molesti, E., Temperton, N., and Barclay, W. S. (2013). Mutations in haemagglutinin that affect receptor binding and pH stability increase replication of a PR8 influenza virus with H5 HA in the upper respiratory tract of ferrets and may contribute to transmissibility. J. Gen. Virol. 94, 1220-1229. doi:10.1099/vir.0.050526-0.
120. Smith, S. E., Gibson, M. S., Wash, R. S., Ferrara, F., Wright, E., Temperton, N., Kellam, P., and Fife, M. (2013). Chicken interferon-inducible transmembrane protein 3 restricts influenza viruses and lyssaviruses in vitro. J. Virol. 87, 12957-66. doi:10.1128/JVI.01443-13.
121. Soneoka, Y., Cannon, P. M., Ramsdale, E. E., Griffiths, J. C., Romano, G., Kingsman, S. M., and Kingsman, a J. (1995). A transient three-plasmid expression system for the production of high titer retroviral vectors. Nucleic Acids Res. 23, 628-633. doi:4c0198 [pii].
122. Su, B., Wurtzer, S., Rameix-Welti, M. A., Dwyer, D., van der Werf, S., Naffakh, N., Clavel, F., and Labrosse, B. (2009). Enhancement of the influenza a hemagglutinin (HA)-mediated cell-cell fusion and virus entry by the viral neuraminidase (NA). PLoS One 4, e8495. doi:10.1371/journal.pone.0008495.
123. Su, C. Y., Wang, S. Y., Shie, J. J., Jeng, K. S., Temperton, N. J., Fang, J. M., Wong, C. H., and Cheng, Y. S. E. (2008a). In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Res. 79, 199-205. doi:10.1016/j.antiviral.2008.03.002.
124. Su, Y., Zhu, X., Wang, Y., Wu, M., and Tien, P. (2008b). Evaluation of Glu11 and Gly8 of the H5N1 influenza hemagglutinin fusion peptide in membrane fusion using pseudotype virus and reverse genetics. Arch. Virol. 153, 247-257. doi:10.1007/s00705-007-1088-9.
125. Sui, J., Hwang, W., Perez, S., Wei, G., Aird, D., Chen, L., Santelli, E., Stec, B., Cadwell, G., Ali, M., et al. (2009). Strutural and Functional bases for broad spectrum neutralization of Avian and human influenza A viruses. Nat Struct Mol Biol 16, 265-273. doi:10.1038/nsmb.1566.Structural.
126. Sui, J., Sheehan, J., Hwang, W. C., Bankston, L. A., Burchett, S. K., Huang, C. Y., Liddington, R. C., Beigel, J. H., and Marasco, W. a. (2011). Wide prevalence of heterosubtypic broadly neutralizing human anti-influenza a antibodies. Clin. Infect. Dis. 52, 1003-1009. doi:10.1093/cid/cir121.
127. Szécsi, J., Boson, B., Johnsson, P., Dupeyrot-Lacas, P., Matrosovich, M., Klenk, H.-D., Klatzmann, D., Volchkov, V., and Cosset, F.-L. (2006a). Induction of neutralising antibodies by virus-like particles harbouring surface proteins from highly pathogenic H5N1 and H7N1 influenza viruses. Virol. J. 3, 70. doi:10.1186/1743-422X-3-70.
128. Szécsi, J., Drury, R., Josserand, V., Grange, M. P., Boson, B., Hartl, I., Schneider, R., Buchholz, C. J., Coll, J. L., Russell, S. J., et al. (2006b). Targeted retroviral vectors displaying a cleavage site-engineered hemagglutinin (HA) through HA-protease interactions. Mol. Ther. 14, 735-744. doi:10.1016/j.ymthe.2006.04.007.
129. Tamura, K., Peterson, D., Peterson, N., Stecher, G., Nei, M., and Kumar, S. (2011). MEGA5: molecular evolutionary genetics analysis using maximum likelihood, evolutionary distance, and maximum parsimony methods. Mol. Biol. Evol. 28, 2731-9. doi:10.1093/molbev/msr121.
130. Tang, D. J., Lam, Y. M., Siu, Y. L., Lam, C. H., Chu, S. L., Peiris, J. S. M., Buchy, P., Nal, B., and Bruzzone, R. (2012). A Single Residue Substitution in the Receptor-Binding Domain of H5N1 Hemagglutinin Is Critical for Packaging into Pseudotyped Lentiviral Particles. PLoS One 7, e43596. doi:10.1371/journal.pone.0043596.
131. Tao, L., Chen, J., Meng, J., Chen, Y., Li, H., Liu, Y., Zheng, Z., and Wang, H. (2013). Enhanced protective efficacy of H5 subtype influenza vaccine with modification of the multibasic cleavage site of hemagglutinin in retroviral pseudotypes. Virol. Sin. 28, 136-145. doi:10.1007/s12250-013-3326-5.
132. Temperton, N. J., Hoschler, K., Major, D., Nicolson, C., Manvell, R., Hien, V. M., Ha, D. Q., de Jong, M., Zambon, M., Takeuchi, Y., et al. (2007). A sensitive retroviral pseudotype assay for influenza H5N1-neutralizing antibodies. Influenza Other Respi. Viruses 1, 105-112. doi:10.1111/j.1750-2659.2007.00016.x.
133. Throsby, M., van den Brink, E., Jongeneelen, M., Poon, L. L. M., Alard, P., Cornelissen, L., Bakker, A., Cox, F., van Deventer, E., Guan, Y., et al. (2008). Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells. PLoS One 3. doi:10.1371/journal.pone.0003942.
134. Tisoncik, J. R., Guo, Y., Cordero, K. S., Yu, J., Wang, J., Cao, Y., and Rong, L. (2011). Identification of critical residues of influenza neuraminidase in viral particle release. Virol. J. 8, 14. doi:10.1186/1743-422X-8-14.
135. Tong, S., Li, Y., Rivailler, P., Conrardy, C., Castillo, D. A. A., Chen, L.-M., Recuenco, S., Ellison, J. A., Davis, C. T., York, I. A., et al. (2012). A distinct lineage of influenza A virus from bats. Proc. Natl. Acad. Sci. 109, 4269-4274. doi:10.1073/pnas.1116200109.
136. Tong, S., Zhu, X., Li, Y., Shi, M., Zhang, J., Bourgeois, M., Yang, H., Chen, X., Recuenco, S., Gomez, J., et al. (2013). New World Bats Harbor Diverse Influenza A Viruses. PLoS Pathog. 9. doi:10.1371/journal.ppat.1003657.
137. Towers, G., Bock, M., Martin, S., Takeuchi, Y., Stoye, J. P., and Danos, O. (2000). A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. U. S. A. 97, 12295-12299. doi:10.1073/pnas.200286297.
138. Tsai, C., Caillet, C., Hu, H., Zhou, F., Ding, H., Zhang, G., Zhou, B., Wang, S., Lu, S., Buchy, P., et al. (2009). Measurement of neutralizing antibody responses against H5N1 clades in immunized mice and ferrets using pseudotypes expressing influenza hemagglutinin and neuraminidase. Vaccine 27, 6777-6790. doi:10.1016/j.vaccine.2009.08.056.
139. Wallerstrom, S., Lagerqvist, N., Temperton, N. J., Cassmer, M., Moreno, A., Karlsson, M., Leijon, M., and Falk, K. I. (2014). Detection of antibodies against H5 and H7 strains in birds: evaluation of influenza pseudovirus particle neutralization tests. Infect. Ecol. Epidemiol. 4, 1-8.
140. Walsh, K. A, and Neurath, H. (1964). Trypsinogen and Chymotrypsinogen As Homologous Proteins. Proc. Natl. Acad. Sci. U. S. A. 52, 884-889. doi:10.1073/pnas.52.4.884.
141. Wang, H., Ma, C., Lu, Y., Ji, X., Pang, Y., Hua, F., Cui, L., Ba, D., and He, W. (2013a). Generation of human neutralizing monoclonal antibodies against the 2009 pandemic H1N1 virus from peripheral blood memory B lymphocytes. Cell. Mol. Immunol. 10, 1-10. doi:10.1038/cmi.2013.25.
142. Wang, J., Cheng, H., Ratia, K., Varhegyi, E., Hendrickson, W. G., Li, J., and Rong, L. (2013b). A Comparative High-Throughput Screening Protocol to Identify Entry Inhibitors of Enveloped Viruses. J. Biomol. Screen. 19, 100-107. doi:10.1177/1087057113494405.
143. Wang, S.-Y., Su, C.-Y., Lin, M., Huang, S.-Y., Huang, W.-I., Wang, C.-C., Wu, Y.-T., Cheng, T.-J. R., Yu, H.-M., Ren, C.-T., et al. (2009). HA-pseudotyped retroviral vectors for influenza antagonist screening. J. Biomol. Screen. Off. J. Soc. Biomol. Screen. 14, 294-302. doi:10.1177/1087057108330786.
144. Wang, W., Anderson, C. M., de Feo, C. J., Zhuang, M., Yang, H., Vassell, R., Xie, H., Ye, Z., Scott, D., and Weiss, C. D. (2011). Cross-neutralizing antibodies to pandemic 2009 H1N1 and recent seasonal H1N1 influenza a strains influenced by a mutation in hemagglutinin subunit 2. PLoS Pathog. 7. doi:10.1371/journal.ppat.1002081.
145. Wang, W., Butler, E. N., Veguilla, V., Vassell, R., Terrig Thomas, J., Moos, M., Ye, Z., Hancock, K., and Weiss, C. D. (2008). Establishment of retroviral pseudotypes with influenza hemagglutinins from H1, H3, and H5 subtypes for sensitive and specific detection of neutralizing antibodies. J. Virol. Methods 153, 111-119. doi:10.1016/j.jviromet.2008.07.015.
146. Wang, W., Castelán-Vega, J. A., Jiménez-Alberto, A., Vassell, R., Ye, Z., and Weiss, C. D. (2010). A mutation in the receptor binding site enhances infectivity of 2009 H1N1 influenza hemagglutinin pseudotypes without changing antigenicity. Virology 407, 374-380. doi:10.1016/j.virol.2010.08.027.
147. Wang, W., Peng, H., Tao, Q., Zhao, X., Tang, H., Tang, Z., Wang, Y., Wang, Y., Zhao, P., and Qi, Z. (2014). Serologic assay for avian-origin influenza A (H7N9) virus in adults of Shanghai, Guangzhou and Yunnan, China. J. Clin. Virol. 60, 305-308. doi:10.1016/j.jcv.2014.04.006.
148. Wang, W., Xie, H., Ye, Z., Vassell, R., and Weiss, C. D. (2010c). Characterization of lentiviral pseudotypes with influenza H5N1 hemagglutinin and their performance in neutralization assays. J. Virol. Methods 165, 305-310. doi:10.1016/j.jviromet.2010.02.009.
149. Wei, C., Boyington, J. C., Dai, K., Houser, K. V, Melissa, B., Kong, W., Yang, Z., Tumpey, T. M., and Nabel, G. J. (2011). Cross-Neutralization of 1918 and 2009 Influenza Viruses: Role of Glycans in Viral Evolution and Va. Sci. Transl. Med. 2, 1-16. doi:10.1126/scitranslmed.3000799.Cross-Neutralization.
150. Wei, C.-J., Boyington, J. C., McTamney, P. M., Kong, W.-P., Pearce, M. B., Xu, L., Andersen, H., Rao, S., Tumpey, T. M., Yang, Z.-Y., et al. (2010). Induction of broadly neutralizing H1N1 influenza antibodies by vaccination. Science 329, 1060-1064. doi:10.1126/science.1192517.
151. Wei, C.-J., Xu, L., Kong, W.-P., Shi, W., Canis, K., Stevens, J., Yang, Z.-Y., Dell, A., Haslam, S. M., Wilson, I. A, et al. (2008). Comparative efficacy of neutralizing antibodies elicited by recombinant hemagglutinin proteins from avian H5N1 influenza virus. J. Virol. 82, 6200-6208. doi:10.1128/JVI.00187-08.
152. Wei, C.-J., Yassine, H. M., McTamney, P. M., Gall, J. G. D., Whittle, J. R. R., Boyington, J. C., and Nabel, G. J. (2012). Elicitation of Broadly Neutralizing Influenza Antibodies in Animals with Previous Influenza Exposure. Sci. Transl. Med. 4, 147ra114-147ra114. doi:10.1126/scitranslmed.3004273.
153. Whittle, J. R. R., Wheatley, a. K., Wu, L., Lingwood, D., Kanekiyo, M., Ma, S. S., Narpala, S. R., Yassine, H. M., Frank, G. M., Yewdell, J. W., et al. (2014). Flow Cytometry Reveals that H5N1 Vaccination Elicits Cross-Reactive Stem-Directed Antibodies from Multiple Ig Heavy-Chain Lineages. J. Virol. 88, 4047-4057. doi:10.1128/JVI.03422-13.
154. Wiley, D. C., and Skehel, J. J. (1987). The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu. Rev. Biochem. 56, 365-94. doi:10.1146/annurev.bi.56.070187.002053.
155. Wrammert, J., Koutsonanos, D., Li, G.-M., Edupuganti, S., Sui, J., Morrissey, M., McCausland, M., Skountzou, I., Hornig, M., Lipkin, W. I., et al. (2011). Broadly cross1324 reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181-193. doi:10.1084/jem.20101352.
156. Wright, E., Hayman, D. T. S., Vaughan, A., Temperton, N. J., Wood, J. L. N., Cunningham, A. a, Suu-Ire, R., Weiss, R. A, and Fooks, A. R. (2010). Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses. Virology 408, 183-9. doi:10.1016/j.virol.2010.09.014.
157. Wu, J., Zhang, F., Wang, M., Xu, C., Song, J., Zhou, J., Lin, X., Zhang, Y., Wu, X., Tan, W., et al. (2010). Characterization of neuraminidases from the highly pathogenic avian H5N1 and 2009 pandemic H1N1 influenza a viruses. PLoS One 5, e15825. doi:10.1371/journal.pone.0015825.
158. Wu, Q., Fang, L., Wu, X., Li, B., Luo, R., Yu, Z., Jin, M., Chen, H., and Xiao, S. (2009). A pseudotype baculovirus-mediated vaccine confers protective immunity against lethal challenge with H5N1 avian influenza virus in mice and chickens. Mol. Immunol. 46, 2210-2217. doi:10.1016/j.molimm.2009.04.017.
159. Yamano, S., Dai, J., and Moursi, A. M. (2010). Comparison of transfection efficiency of nonviral gene transfer reagents. Mol. Biotechnol. 46, 287-300. doi:10.1007/s12033-010-9302-5.
160. Yang, D., Chung, Y., Lai, Y., Lai, C., Liu, H., and Hu, Y. (2007). Avian Influenza Virus Hemagglutinin Display on Baculovirus Envelope: Cytoplasmic Domain Affects Virus Properties and Vaccine Potential. Am. Soc. Gene Ther. 15, 989-996. doi:10.1038/mt.sj.6300131.Introduction.
161. Yang, J., Li, W., Long, Y., Song, S., Liu, J., Zhang, X., Wang, X., Jiang, S., and Liao, G. (2014). Reliability of Pseudotyped Influenza Viral Particles in Neutralizing Antibody Detection. PLoS One 9, e113629. doi:10.1371/journal.pone.0113629.
162. Zhang, S., Xiao, L., Zhou, H., Yu, Z., Chen, H., Guo, A., and Jin, M. (2008). Generation and characterization of an H5N1 avian influenza virus hemagglutinin glycoprotein pseudotyped lentivi 1350 rus. J. Virol. Methods 154, 99-103. doi:10.1016/j.jviromet.2008.08.016.
163. Zhang, Y., Lin, X., Wang, G., Zhou, J., Lu, J., Zhao, H., Zhang, F., Wu, J., Xu, C., Du, N., et al. (2010). Neuraminidase and hemagglutinin matching patterns of a highly pathogenic avian and two pandemic H1N1 influenza A viruses. PLoS One 5. doi:10.1371/journal.pone.0009167.
164. Zhang, Y., Lin, X., Zhang, F., Wu, J., Tan, W., Bi, S., Zhou, J., Shu, Y., and Wang, Y. (2009). Hemagglutinin and neuraminidase matching patterns of two influenza A virus strains related to the 1918 and 2009 global pandemics. Biochem. Biophys. Res. Commun. 387, 405-8. doi:10.1016/j.bbrc.2009.07.040.
165. Zhao, R., Cui, S., Guo, L., Wu, C., Gonzalez, R., Paranhos-Baccalà, G., Vernet, G., Wang, J., and Hung, T. (2011). Identification of a highly conserved H1 subtype-specific epitope with diagnostic potential in the hemagglutinin protein of influenza A virus. PLoS One 6, e23374. doi:10.1371/journal.pone.0023374.
166. Zheng, L., Chi, M., Zhonghua, L., and Wei, H. (2012). Serologic cross-reactivity among humans and birds infected with highly pathogenic avian influenza A subtype H5N1 viruses in China. Immunol. Lett. 135, 59-63. doi:10.1016/j.imlet.2010.09.012.Serologic.
167. Zhou, F., Wang, G., Buchy, P., Cai, Z., Chen, H., Chen, Z., Cheng, G., Wan, X.-F., Deubel, V., and Zhou, P. (2012). A Triclade DNA Vaccine Designed on the Basis of a Comprehensive Serologic Study Elicits Neutralizing Antibody Responses against All Clades and Subclades of Highly Pathogenic Avian Influenza H5N1 Viruses. J. Virol. 86, 6970-6978. doi:10.1128/JVI.06930-11.
168. Zimmer, G., Locher, S., Berger Rentsch, M., and Halbherr, S. J. (2014). Pseudotyping of vesicular stomatitis virus with the envelope glycoproteins of highly pathogenic avian influenza viruses. J. Gen. Virol. 95, 1634-9. doi:10.1099/vir.0.065201-0.
169. Zmora, P., Blazejewska, P., Moldenhauer, A.-S., Welsch, K., Nehlmeier, I., Wu, Q., Schneider, H., Pohlmann, S., and Bertram, S. (2014). DESC1 and MSPL Activate Influenza A Viruses and Emerging Coronaviruses for Host Cell Entry. J. Virol. 88, 12087-12097. doi:10.1128/JVI.01427-14.
170. Zufferey, R., Dull, T., Mandel, R. J., Bukovsky, a, Quiroz, D., Naldini, L., and Trono, D. (1998). Self-inactivating lentivirus vector for safe and efficient in vivo gene delivery. J. Virol. 72, 9873-9880. doi:99030895.
171. Zufferey, R., Nagy, D., Mandel, R. J., Naldini, L., and Trono, D. (1997). Multiply attenuated lentiviral vector achieves efficient gene delivery in vivo. Nat. Biotechnol. 15, 871-875. doi:10.1038/nbt0997-871.